Benitec Biopharma (BNTC) Depreciation & Amortization (CF) (2019 - 2025)

Benitec Biopharma has reported Depreciation & Amortization (CF) over the past 7 years, most recently at $14000.0 for Q4 2025.

  • Quarterly results put Depreciation & Amortization (CF) at $14000.0 for Q4 2025, changed 0.0% from a year ago — trailing twelve months through Dec 2025 was $54000.0 (down 40.0% YoY), and the annual figure for FY2025 was $66000.0, down 24.14%.
  • Depreciation & Amortization (CF) reached $14000.0 in Q4 2025 per BNTC's latest filing, up from $13000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $67000.0 in Q1 2021 and bottomed at $6000.0 in Q2 2022.
  • Median Depreciation & Amortization (CF) over the past 5 years was $25000.0 (2024), compared with a mean of $30100.0.
  • The largest annual shift saw Depreciation & Amortization (CF) crashed 88.46% in 2022 before it skyrocketed 250.0% in 2023.
  • Over 5 years, Depreciation & Amortization (CF) stood at $55000.0 in 2021, then fell by 25.45% to $41000.0 in 2022, then crashed by 58.54% to $17000.0 in 2023, then decreased by 17.65% to $14000.0 in 2024, then changed by 0.0% to $14000.0 in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for BNTC at $14000.0 in Q4 2025, $13000.0 in Q3 2025, and $14000.0 in Q2 2025.